Veracyte Inc. Stock
Price
Target price
?
?
-0.540%
-0.2
-0.540%
-
07:46 / Stuttgart Stock Exchange
WKN: A1W7EA / Name: Veracyte / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Veracyte Inc. Stock
The price for the Veracyte Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.540%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Veracyte Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Veracyte Inc. in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Veracyte Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Veracyte Inc. | -0.540% | -3.297% | -0.565% | -10.204% | -2.222% | 55.649% | -20.362% |
| Ardelyx Inc. | -2.140% | 15.556% | 40.502% | 45.188% | 39.129% | 136.634% | 17.868% |
| Evolus Inc | -0.970% | 0.000% | -28.475% | -56.939% | -22.569% | -55.344% | -9.325% |
| Champions Oncology Inc | -2.540% | 0.855% | 0.855% | -36.216% | 1.724% | 47.500% | -35.519% |
News
Veracyte (VCYT) Q2 Revenue Jumps 14%
Veracyte (NASDAQ:VCYT), a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and
